Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Liver function tests during administration of triphasic contraceptives containing Norgestimate].

J Paseka1, V Unzeitig, D Cibula

  • 1Lékarské oddĕlení Janssen-Cilag, Praha.

Ceska Gynekologie
|March 29, 2001
PubMed
Summary

This study found no significant liver function changes in women using a triphasic oral contraceptive with norgestimate and ethinylestradiol for six months. Routine liver enzyme tests are not recommended for healthy combined oral contraceptive users.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective comparison of diagnostic accuracy of ultrasound, PET/CT and DW-MRI for preoperative assessment of pelvic lymph nodes in cervical cancer patients: results of the CANNES trial.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2026
Same author

Comparison of ultrasound with computed tomography and whole-body diffusion-weighted MRI in prediction of surgical outcome using ESMO-ESGO criteria in patients with tubo-ovarian carcinoma: prospective ISAAC study.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2025
Same author

The role of HPV testing in the follow-up of patients in different clinical scenarios after diagnosis of cervical preinvasive lesions and carcinomas.

Expert review of anticancer therapy·2025
Same author

Practical recommendations for the use of PARP inhibitors in the treatment of ovarian cancer.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2025
Same author

Dostarlimab and niraparib in primary advanced ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Ultrasound examiners' ability to describe ovarian cancer spread using preacquired ultrasound videoclips from a selected patient sample with high prevalence of cancer spread.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2025

Area of Science:

  • Pharmacology
  • Hepatology
  • Women's Health

Background:

  • Combined oral contraceptives (COCs) are widely used for family planning.
  • Monitoring liver function in COC users is a clinical consideration.
  • Triphasic oral contraceptives offer varying hormone doses throughout the cycle.

Purpose of the Study:

  • To assess the impact of a specific triphasic oral contraceptive (Pramino) on liver enzymes and bilirubin.
  • To evaluate changes in liver function tests after six cycles of COC use.
  • To determine the clinical significance of any observed alterations in liver function.

Main Methods:

  • A prospective, open-label, multicentric phase IV study.
  • Serum levels of ALT, AST, GMT, and bilirubin were measured before and after six cycles of Pramino.

Related Experiment Videos

  • Statistical analysis included subgroup evaluations and percentage variations from reference limits.

    • Main Results:

    • No clinically significant changes in liver function tests were observed.
    • Mild increases in gamma-glutamyltransferase (GMT) were noted but remained within normal limits.
    • Pre-existing elevated liver enzymes either remained stable or normalized during the study period.

    Conclusions:

    • Triphasic oral contraceptives containing norgestimate and ethinylestradiol do not cause clinically significant liver function abnormalities.
    • Routine monitoring of liver function tests is not indicated for healthy users of this combined oral contraceptive.
    • The dynamic changes in liver function tests do not support their use for routine monitoring in this population.